The U.S. Department of Commerce issued procedures giving companies 30 days to submit company-specific onshoring plans to qualify for agreements tied to Section 232 biopharma tariffs. The notice outlines how firms seeking relief must file the plans within the stated window as implementation approaches, adding near-term compliance pressure across drug and ingredient supply chains.